InvestorsHub Logo
Followers 4
Posts 1608
Boards Moderated 0
Alias Born 09/07/2006

Re: John266 post# 49

Friday, 12/08/2006 9:56:40 AM

Friday, December 08, 2006 9:56:40 AM

Post# of 413
If someone is betting on indiplon royalties as a cash measure to solve ANY problem I believe IMO he is dead wrong!

I do agree that bicifadine still has lots of partnerships potentials. Also the OA PII should be over by now and results available soon.

I do share the same optimism about the two compounds (21,947 and 216,303). The Company received 35M upfront a while back ago and can now re-license those compounds for higher upfront payments and lower l.t. payments. I believe something similar happened to REGN with Sanofi and while anyone said REGN's drug was dead since Sanofi returned the rights, a little time later REGN was able to strike a lucrative partnership with another Company.

Time will tell, but cash might come now from:

1) Dov 21,947;
2) Dov 216,303;
3) Bicifadine for chronic and acute pain;
4) Bicifadine for OA indication or other indications related to the compound + ibuprofen;
5) Dov Diltiazem;
6) Dov 102,677.

I would be very surprised to see that they aren't able to raise 70M out of all these drugs.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.